Spots Global Cancer Trial Database for brca1 mutation
Every month we try and update this database with for brca1 mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | NCT04651920 | Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis Homologous Reco... | Evaluation of h... | 18 Years - | Peking Union Medical College Hospital | |
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | NCT06065059 | Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ov... BRCA-Associated... HRD Positive Ad... | TNG348 Olaparib | 18 Years - | Tango Therapeutics, Inc. | |
Depression and Body Image Distress Following Mastectomy With Reconstruction | NCT03428399 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | Psychosocial va... | 18 Years - | Massachusetts General Hospital | |
Combination Therapy in Cancers With Mutations in DNA Repair Genes | NCT05694715 | Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta... | Niraparib Irinotecan | 18 Years - | University of California, San Francisco | |
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations | NCT05498272 | Prostate Cancer BRCA1 Mutation BRCA2 Mutation Prostatic Adeno... High-Risk Cance... | Olaparib LHRH agonist | 18 Years - | Hoosier Cancer Research Network | |
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | NCT05485766 | Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated... | Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg... | 18 Years - | Okayama University | |
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) | NCT04055038 | Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy | Platinum-Based ... Conventional ch... | 18 Years - 70 Years | Blokhin's Russian Cancer Research Center | |
Prostate Cancer Genetic Risk Evaluation and Screening Study | NCT05129605 | Prostatic Neopl... Prostate Cancer BRCA2 Mutation BRCA1 Mutation ATM Gene Mutati... MMR Mutation Lynch Syndrome Genetic Predisp... | Prostate cancer... | 35 Years - 74 Years | Massachusetts General Hospital | |
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening | NCT04273542 | Breast Cancer F... BRCA1 Mutation BRCA2 Mutation | liquid biopsy | 18 Years - | Centre Jean Perrin | |
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | NCT01472783 | Recurrent, Epit... | Veliparib | 18 Years - | Vejle Hospital | |
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | NCT05537844 | Ovarian Cancer High Grade Sero... Carcinosarcoma,... Fallopian Tube ... Primary Periton... BRCA1 Mutation BRCA2 Mutation | 16 Years - | Cancer Research UK, Glasgow | ||
Genetic Education in BRCA Families | NCT03544983 | BRCA1 Mutation BRCA2 Mutation | Web + Streamlin... | 21 Years - 75 Years | Georgetown University | |
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | NCT06177171 | BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati... | Olaparib ASTX727 | 18 Years - | University of California, San Francisco | |
Decision Support for BRCA Testing in Ethnically Diverse Women | NCT03470402 | Breast Cancer BRCA1 Mutation BRCA2 Mutation Ovarian Cancer | RealRisks BNAV iNYP Standard Educat... High-Risk Messa... | 21 Years - 75 Years | Columbia University | |
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma | NCT00617656 | Non Small Cell ... BRCA1 Mutation | Cisplatin, Doce... Gemcitabine, Ci... Docetaxel, Cisp... Docetaxel | 18 Years - | Spanish Lung Cancer Group | |
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | NCT06065059 | Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ov... BRCA-Associated... HRD Positive Ad... | TNG348 Olaparib | 18 Years - | Tango Therapeutics, Inc. | |
Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing | NCT03475979 | Breast Cancer BRCA1 Mutation BRCA2 Mutation Recurrent Breas... Metachronous Ne... | 25 Years - 75 Years | Seoul National University Hospital | ||
Health After eaRly Menopause Due to Oophorectomy | NCT03835793 | Surgical Menopa... BRCA1 Mutation BRCA2 Mutation Cardiovascular ... Bone Mineral De... Cognitive Decli... Quality of Life Menopause Surgi... | CAC-score | 55 Years - | The Netherlands Cancer Institute | |
Chemo-free BRCA-targeted Neoadjuvant Strategy | NCT05209529 | TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation | olaparib Durvalumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | NCT06380660 | Solid Tumor, Ad... BRCA1 Mutation BRCA2 Mutation Ovarian Cancer Breast Cancer Prostate Cancer | ACE-86225106 ta... | 18 Years - | Acerand Therapeutics Limited | |
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance | NCT02974842 | BRCA1 Mutation BRCA2 Mutation Atypia Suspicio... | MAKO 7 | 18 Years - | nVision Medical | |
3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women | NCT01409226 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | 3.0-T MRI biopsy | 18 Years - 70 Years | NYU Langone Health | |
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | NCT04711109 | BRCA1 Mutation Breast Cancer Breast Diseases Breast Neoplasm... Breast Carcinom... Neoplasms | Denosumab Placebo Quality-of-Life... | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations | NCT00700778 | BRCA1 Mutation Breast Cancer | recombinant hum... microarray anal... immunohistochem... laboratory biom... needle biopsy | 20 Years - 40 Years | Fox Chase Cancer Center | |
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | NCT05537844 | Ovarian Cancer High Grade Sero... Carcinosarcoma,... Fallopian Tube ... Primary Periton... BRCA1 Mutation BRCA2 Mutation | 16 Years - | Cancer Research UK, Glasgow | ||
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | NCT02873975 | Advanced Cancer... | LY2606368 | 18 Years - | Dana-Farber Cancer Institute | |
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development | NCT00381927 | Breast Cancer | Physician Couns... | 18 Years - | Baystate Medical Center | |
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) | NCT04055038 | Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy | Platinum-Based ... Conventional ch... | 18 Years - 70 Years | Blokhin's Russian Cancer Research Center | |
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland | NCT01630226 | BRCA1 Mutation Breast Cancer I... | Neoadjuvant Cis... | 20 Years - 70 Years | Pomeranian Medical University Szczecin | |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
Functional Analysis of BRCAness | NCT04780945 | Ovarian Neoplas... Homologous Reco... BRCA1 Mutation BRCA2 Mutation | Functional RAD5... Olaparib Oral P... | 18 Years - | Leiden University Medical Center | |
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction | NCT01591746 | Breast Cancer Pain, Postopera... BRCA1 Mutation BRCA2 Mutation Breast Diseases Neoplasms | Botulinum Toxin... Placebo | 18 Years - | Mayo Clinic | |
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation. | NCT05097274 | Prostate Cancer BRCA1 Mutation BRCA2 Mutation | MRI pelvis or C... Whole body bone... PET-CT imaging | 18 Years - | Institute of Cancer Research, United Kingdom | |
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients | NCT05410951 | Lobular Breast ... Lobular in Situ... BRCA1 Mutation BRCA2 Mutation | Illumina panel | 18 Years - 99 Years | European Institute of Oncology | |
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening | NCT04273542 | Breast Cancer F... BRCA1 Mutation BRCA2 Mutation | liquid biopsy | 18 Years - | Centre Jean Perrin | |
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01) | NCT02608346 | Women With BRCA... | Blood sampling | 30 Years - | Institut Curie | |
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations | NCT00700778 | BRCA1 Mutation Breast Cancer | recombinant hum... microarray anal... immunohistochem... laboratory biom... needle biopsy | 20 Years - 40 Years | Fox Chase Cancer Center | |
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) | NCT04055038 | Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy | Platinum-Based ... Conventional ch... | 18 Years - 70 Years | Blokhin's Russian Cancer Research Center | |
Chemo-free BRCA-targeted Neoadjuvant Strategy | NCT05209529 | TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation | olaparib Durvalumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | NCT01670500 | Breast Cancer | Cisplatin Cyclophosphamid... Doxorubicin | 18 Years - | Dana-Farber Cancer Institute | |
Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM) | NCT04866992 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Ductal Carcinom... Prognostic Stag... Prognostic Stag... BRCA1 Mutation BRCA2 Mutation | 18 Years - | University of Texas Southwestern Medical Center | ||
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients | NCT05410951 | Lobular Breast ... Lobular in Situ... BRCA1 Mutation BRCA2 Mutation | Illumina panel | 18 Years - 99 Years | European Institute of Oncology | |
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction | NCT04108117 | Postoperative C... Recurrence Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation Surgery Surgery--Compli... | Robotic nipple ... | - | Severance Hospital | |
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | NCT04190667 | Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis | Genomic testing | 18 Years - | Peking Union Medical College Hospital | |
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care | NCT02957981 | Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation | Web-based Couns... Standard Care | 25 Years - 70 Years | Georgetown University | |
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland | NCT01630226 | BRCA1 Mutation Breast Cancer I... | Neoadjuvant Cis... | 20 Years - 70 Years | Pomeranian Medical University Szczecin | |
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care | NCT02957981 | Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation | Web-based Couns... Standard Care | 25 Years - 70 Years | Georgetown University | |
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01) | NCT02608346 | Women With BRCA... | Blood sampling | 30 Years - | Institut Curie | |
Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients | NCT01611727 | BRCA1 Mutation Metastatic Brea... | Cisplatin | 18 Years - | Pomeranian Medical University Szczecin | |
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | NCT06395519 | Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer | ETX-19477 | 18 Years - | 858 Therapeutics, Inc. | |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers | NCT03495609 | hCG BRCA1 Mutation BRCA2 Mutation | Ovitrelle | 18 Years - 30 Years | University Hospital, Ghent | |
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction | NCT04108117 | Postoperative C... Recurrence Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation Surgery Surgery--Compli... | Robotic nipple ... | - | Severance Hospital | |
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01) | NCT02608346 | Women With BRCA... | Blood sampling | 30 Years - | Institut Curie | |
Radical Fimbriectomy for Young BRCA Mutation Carriers | NCT01608074 | BRCA1 Mutation BRCA2 Mutation Hereditary Brea... | Radical fimbrie... Histopathology ... | 35 Years - | Centre Oscar Lambret | |
Dietary Intervention and BRCA Penetrance | NCT03066856 | Dietary Modific... BRCA1 Mutation BRCA2 Mutation Breast Cancer | Dietary interve... | 18 Years - 70 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
Web-based Family History Tool | NCT04890327 | Gynecologic Can... Breast Cancer BRCA1 Mutation BRCA2 Mutation | Web-based famil... | 18 Years - 100 Years | Weill Medical College of Cornell University | |
Liquid Biopsy Evaluation and Repository Development at Princess Margaret | NCT03702309 | Cancer Breast Cancer Lung Cancer Colon Cancer Ovarian Cancer Melanoma Lymphoma Leukemia Mutation Lynch Syndrome Cowden Syndrome BRCA1 Mutation BRCA2 Mutation Uterine Cancer Myeloma Kidney Cancer Head and Neck C... Meningioma | 18 Years - | University Health Network, Toronto | ||
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma | NCT00617656 | Non Small Cell ... BRCA1 Mutation | Cisplatin, Doce... Gemcitabine, Ci... Docetaxel, Cisp... Docetaxel | 18 Years - | Spanish Lung Cancer Group |